ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 97

Identification of Tuberculosis in Rheumatoid Arthritis Patients Initiating Therapy with Biologic or Non-Biologic Disease-Modifying Anti-Rheumatic Drugs Using Health Insurance Claims Data

T Simon1, N Liu2, N Baker3, N Lin2 and V Hoffman4, 1Bristol-Myers Squibb, Hopewell, NJ, 2Optum Epidemiology, Waltham, MA, 3Bristol-Myers Squibb, Hopewell, MA, 4Optum Epidemiology, Ann Arbor, MI

Meeting: 2014 ACR/ARHP Annual Meeting

Keywords: Biologics, DMARDs and tuberculosis

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Title: Health Services Research

Session Type: Abstract Submissions (ACR)

Background/Purpose: Biologic DMARDs used for the treatment of RA may increase the risk of tuberculosis (TB).1 Large healthcare claims databases are useful in assessing rare events such as TB, but confirmation of these events can be challenging. As part of an ongoing post-marketing safety evaluation, we sought to characterize potential TB cases in claims data among RA patients initiating biologic and non-biologic DMARDs.

Methods: A prospective cohort study of adults who initiated biologic or non-biologic DMARDs and who had at least 6 months’ prior continuous health plan enrollment (baseline) and a baseline claim for RA (International Classification of Diseases, 9th Revision [ICD-9] 714.xx) between December 1, 2005 and March 31, 2013 was conducted using administrative data from a large United States healthcare insurer. Potential TB events following drug initiation were identified with diagnosis codes associated with healthcare claims (ICD-9 010.xx- 018.xx) and characterized using criteria from a published validation algorithm for TB detection by Calderwood et al. (2010)2, including the presence of claims suggestive of at least two TB treatments (e.g., pyrazinamide, rifampin, isoniazid, ethambutol) within 60 days, prescription for pyrazinamide, and acid-fast bacilli (AFB) testing in the preceding 60 days or subsequent 14 days. Potential TB events were also characterized by the presence of chest x-ray claims within 60 days.

Results: We identified 15,183 biologic DMARD initiators and 50,492 non-biologic DMARD initiators contributing 32,230 and 100,580 person-years of follow-up, respectively. Biologic DMARD initiators were more likely than non-biologic DMARD initiators to have previously used another biologic during the baseline period (20% vs 9%) and more likely to have a baseline claim for a TB skin test (26% vs 4%). A total of 251 potential TB events were identified during follow-up, 59 among biologic DMARD initiators and 192 among non-biologic DMARD initiators. Among the potential cases, 2 (3%) biologic DMARD initiators and 2 (1%) non-biologic DMARD initiators had claims for pyrazinamide, and 4 (7%) biologic DMARD initiators and 4 (2%) non-biologic DMARD initiators had claims for at least 2 different anti-TB medications. A total of 5 (8%) potential cases among biologic DMARD initiators and 6 (3%) potential cases among non-biologic DMARD initiators had an AFB test claim. A total of 28 (47%) potential cases among biologic DMARD initiators and 103 (54%) potential cases among non-biologic DMARD initiators had a claim for chest x-ray.  

Conclusion: Few potential TB events identified on the basis of diagnosis codes had additional supporting claims. Claims-based algorithms based on diagnosis codes alone are likely insufficient for accurate identification of TB cases in administrative data. Consideration of claims indicative of TB treatment or diagnostic work-up in combination with diagnosis codes may improve identification of TB events in safety surveillance.

 

1. Brassard P, et al. Clin Infect Dis 2006;43:717–22.

2. Calderwood MS, et al. Public Health Rep 2010;125:843–50.

 


Disclosure:

T. Simon,

Bristol-Myers Squibb,

3;

N. Liu,
None;

N. Baker,

Bristol-Myers Squibb,

3;

N. Lin,

Bristol-Myers Squibb,

2;

V. Hoffman,

Optum Epidemiology,

3.

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2014 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/identification-of-tuberculosis-in-rheumatoid-arthritis-patients-initiating-therapy-with-biologic-or-non-biologic-disease-modifying-anti-rheumatic-drugs-using-health-insurance-claims-data/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology